GlassScriptPhysician profile
Renee Harris
NPI 1043350895
$3,297.30
in general payments reported to CMS, 2019-2025
22 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $225 · 2021: $212 · 2022: $479 · 2023: $650 · 2024: $491 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $679.35 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $652.56 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $386.67 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $363.79 | 2020-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $241.65 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $139.21 | 2022-2025 | |
| Alkermes, INC. | $112.20 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Supernus Pharmaceuticals, INC. | $108.15 | 2022-2025 | Qelbree, Qelbree |
| Indivior INC. | $106.46 | 2023-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $81.96 | 2023-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $69.57 | 2019-2025 | Trintellix |
| Uswm, LLC | $62.02 | 2023-2024 | Lucemyra |
| Teva Pharmaceuticals USA, INC. | $49.94 | 2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $48.92 | 2019-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $33.48 | 2025 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.69 | 2024 | |
| Orexo US, INC. | $30.74 | 2024-2025 | Zubsolv |
| Gilead Sciences, INC. | $30.22 | 2025 | |
| Ironshore Pharmaceuticals INC. | $22.71 | 2024 | |
| Corium, LLC | $17.97 | 2022 | |
| Boston Scientific Corporation | $14.98 | 2022 | |
| Eisai INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.